Form 4: Cryoport Director Reports Significant Stock and Option Grants Alongside Share Sale

A recent SEC Form 4 filing reveals Cryoport, Inc. Director Ramkumar Mandalam received substantial equity grants while also executing a sale of common stock.

Summary

• Cryoport, Inc. Director Ramkumar Mandalam reported changes in his beneficial ownership of company securities.
• On June 6, 2025, Mr. Mandalam was granted 23,214 restricted stock rights, which will vest in full on June 6, 2026, converting to common stock on a one-for-one basis.
• Concurrently on June 6, 2025, he was granted 41,098 options to buy common stock at an exercise price of $7.00, with vesting occurring monthly (1/12th) starting July 6, 2025, and expiring on June 6, 2032.
• On June 9, 2025, Mr. Mandalam sold 5,622 shares of Cryoport common stock at a weighted average price of $7.0567 per share.
• Following these transactions, Mr. Mandalam beneficially owns 77,089 shares of common stock and 41,098 options.

Sentiment

Score: 6

Explanation: The sentiment is moderately positive due to the significant equity grants (restricted stock and options) which align the director's interests with the company's long-term performance. The sale of a portion of common stock is a minor negative, but typical for liquidity management and is outweighed by the new grants.

Positives

• The grant of 23,214 restricted stock rights aligns the director's long-term interests with shareholder value, as these shares vest over time.
• The acquisition of 41,098 stock options provides an incentive for the director to contribute to the company's growth and stock price appreciation.

Negatives

• A director's sale of 5,622 shares of common stock, even if for personal liquidity, could be perceived negatively by investors as it reduces their direct equity stake in the company.

Future Outlook

The document indicates future vesting events for both restricted stock rights (June 6, 2026) and stock options (monthly vesting starting July 6, 2025, through June 6, 2032), which will impact the director's beneficial ownership over time.

Industry Context

This Form 4 filing is a routine disclosure of insider trading activity and does not provide broader industry context or trends. It reflects individual compensation and investment decisions within Cryoport, Inc.

Stakeholder Impact

• Shareholders: The director's increased equity alignment through grants could be viewed positively, while the sale might be viewed neutrally or slightly negatively depending on individual investor interpretation.

Next Steps

• Vesting of 23,214 restricted stock rights on June 6, 2026.
• Ongoing monthly vesting of 41,098 stock options starting July 6, 2025.

Key Dates

Keywords

Cryoport, CYRX, SEC Form 4, Insider Trading, Stock Options, Restricted Stock Units, Director Transactions, Beneficial Ownership, Equity Grants, Share Sale